| UHC Medicaid Medical & Drug | Erythropoiesis-Stimulating Agents – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Evenity® (Romosozumab-Aqqg) – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Evkeeza® (Evinacumab-Dgnb) – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Factor Mimetics and Rebalancing Agents for Hemophilia – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Gamifant® (Emapalumab-Lzsg) – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Gazyva® (Obinutuzumab) – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Givlaari® (Givosiran) – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Ilaris® (Canakinumab) – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Intravenous Iron Replacement Therapy (Feraheme®, Injectafer®, & Monoferric®) – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Lemtrada® (Alemtuzumab) – Community Plan Medical Benefit Drug Policy | 2026-04-01 |